[Anemia in chronic kidney disease].

Area of Science:

• Nephrology
• Hematology

Background:

• Anemia is a common complication in end-stage chronic kidney disease (CKD).
• It is characterized by low hemoglobin levels, often below 13 g/dL for adults and 12 g/dL for women.
• Inadequate erythropoietin production is a primary cause of anemia in CKD.

Purpose of the Study:

• To review the role of erythropoiesis-stimulating agents (ESAs) in managing anemia in chronic kidney disease.
• To evaluate the risks and benefits associated with achieving normal hemoglobin levels using ESAs.
• To provide guidance on the optimal hemoglobin targets and dosing strategies for ESAs in CKD patients.

Main Methods:

• Review of randomized trials and clinical studies on anemia management in CKD.
• Analysis of data regarding hemoglobin levels, ESA use, mortality, and cardiovascular complications.
• Synthesis of current evidence to inform treatment strategies.

Main Results:

• ESAs improve clinical outcomes and reduce transfusion needs in CKD anemia.
• Achieving normal or near-normal hemoglobin levels with ESAs has not shown improved survival or reduced cardiovascular risk.
• Increased risks of mortality and cardiovascular complications are associated with ESAs when targeting higher hemoglobin levels.

Conclusions:

• The ideal hemoglobin level for ESA treatment in CKD remains uncertain.
• Current evidence suggests that targeting normal hemoglobin levels with ESAs may increase risks.
• A conservative approach using the lowest effective ESA dose is recommended pending further research.